These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 19503958)

  • 1. [Principle of protection and treatment of rare genetic diseases in Brazil: the case of lysosomal storage disorders].
    Boy R; Schramm FR
    Cad Saude Publica; 2009 Jun; 25(6):1276-84. PubMed ID: 19503958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orphan drugs revisited.
    McCabe C; Tsuchiya A; Claxton K; Raftery J
    QJM; 2006 May; 99(5):341-5; discussion 350-1. PubMed ID: 16504983
    [No Abstract]   [Full Text] [Related]  

  • 3. EU to review rare disease drugs market exclusivity.
    Sheridan C
    Nat Biotechnol; 2004 Sep; 22(9):1061. PubMed ID: 15340455
    [No Abstract]   [Full Text] [Related]  

  • 4. A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation.
    Pinxten W; Denier Y; Dooms M; Cassiman JJ; Dierickx K
    J Med Ethics; 2012 Mar; 38(3):148-53. PubMed ID: 21947805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [High cost drugs for rare diseases in Brazil: the case of lysosomal storage disorders].
    de Souza MV; Krug BC; Picon PD; Schwartz IV
    Cien Saude Colet; 2010 Nov; 15 Suppl 3():3443-54. PubMed ID: 21120332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pressure for drug development in lysosomal storage disorders - a quantitative analysis thirty years beyond the US orphan drug act.
    Mechler K; Mountford WK; Hoffmann GF; Ries M
    Orphanet J Rare Dis; 2015 Apr; 10():46. PubMed ID: 25896727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bioethics and Brazilian health policies].
    Zoboli E; Fortes PA
    J Int Bioethique; 2008; 19(1-2):121-8, 199. PubMed ID: 18664005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products.
    Dear JW; Lilitkarntakul P; Webb DJ
    Br J Clin Pharmacol; 2006 Sep; 62(3):264-71. PubMed ID: 16934041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orphan Drugs in Oncology.
    Korchagina D; Jaroslawski S; Jadot G; Toumi M
    Recent Results Cancer Res; 2019; 213():109-142. PubMed ID: 30543010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lucrative niches: how drugs for rare diseases became lifeline for companies.
    Anand G
    Wall St J (East Ed); 2005 Nov; ():A1, A18. PubMed ID: 16502531
    [No Abstract]   [Full Text] [Related]  

  • 11. Policymaking for Orphan Drugs and Its Challenges.
    Rhee TG
    AMA J Ethics; 2015 Aug; 17(8):776-9. PubMed ID: 26270879
    [No Abstract]   [Full Text] [Related]  

  • 12. [The bioethics of protection and the state's role: moral problems in unequal access to drinking water].
    Pontes CA; Schramm FR
    Cad Saude Publica; 2004; 20(5):1319-27. PubMed ID: 15486675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of 11 national policies for rare diseases in the context of key patient needs.
    Dharssi S; Wong-Rieger D; Harold M; Terry S
    Orphanet J Rare Dis; 2017 Mar; 12(1):63. PubMed ID: 28359278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orphan drug policies and use in pediatric nephrology.
    Karpman D; Höglund P
    Pediatr Nephrol; 2017 Jan; 32(1):1-6. PubMed ID: 27738765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ethical issues related to the access to orphan drugs in Brazil: the case of mucopolysaccharidosis type I.
    Boy R; Schwartz IV; Krug BC; Santana-da-Silva LC; Steiner CE; Acosta AX; Ribeiro EM; Galera MF; Leivas PG; Braz M
    J Med Ethics; 2011 Apr; 37(4):233-9. PubMed ID: 21266385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Our moral obligations in caring for patients with orphan cancers.
    Fernandez CV
    CMAJ; 2007 Jan; 176(3):297, 299. PubMed ID: 17261816
    [No Abstract]   [Full Text] [Related]  

  • 17. Ethical dilemmas about orphan drugs for orphan diseases.
    Isaacs D
    J Paediatr Child Health; 2014 Apr; 50(4):249-50. PubMed ID: 24698059
    [No Abstract]   [Full Text] [Related]  

  • 18. Awareness of orphan therapies offer opportunities for pharmacists.
    Traynor K
    Am J Health Syst Pharm; 2013 Sep; 70(18):1564, 1566. PubMed ID: 23988596
    [No Abstract]   [Full Text] [Related]  

  • 19. The challenges of orphan drugs and orphan diseases: real and imagined.
    Hudson I; Breckenridge A
    Clin Pharmacol Ther; 2012 Aug; 92(2):151-3. PubMed ID: 22814659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Confusion over Article 8.
    Tambuyzer E
    EMBO Rep; 2005 Aug; 6(8):690. PubMed ID: 16065056
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.